ORR was 72.7% (n = 8) in patients with HER2-mutant NSCLC, of whom six had insertions in exon 20; mPFS was 11.3 months and mDoR 9.9 months. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.